Elicio Therapeutics Financial Results
Elicio Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its camupepimut clinical program. The company highlighted Phase 2 AMPLIFY-7P data in pancreatic cancer showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, which will inform its Phase 3 strategy.
“We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late-stage development and refine our Phase 3 strategy in adjuvant PDAC.”
Robert Connelly, President and Chief Executive Officer
“The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.”
Robert Connelly, President and Chief Executive Officer